Indian drug major Dr Reddy’s Laboratories (BSE: 500124), through its wholly-owned US subsidiary Promius Pharma, has out-licensed the future development, manufacturing and commercialization rights of DFD-06, a topical high potency steroid, to Encore Dermatology.
The drug is intended to be used for treatment of moderate to severe plaque psoriasis. Privately-held Encore Dermatology was formed in 2014 as a vehicle for three ex-Valeant dermatological products.
Dr Reddy’s shares gained 2.67% by close of BSE trading on Tuesday at 1,984.85 rupees.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze